P450 oxidoreductase: Genotyping, expression, purification of recombinant protein, and activity assessments of wild-type and mutant protein

Methods in Molecular Biology

Volumn 987, Issue , 2013, Pages 225-237

  Agrawal, Vishal ^a   Miller, Walter L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Enzyme activity; Genotyping; Heterologous expression; Mutant; P450 reductase; Puri fication

Indexed keywords

AMINO ACID; CYTOCHROME P450 REDUCTASE; MUTANT PROTEIN; RECOMBINANT PROTEIN; DNA; NICKEL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

AMINO ACID SEQUENCE; ARTICLE; ENZYME ACTIVITY; ENZYME POLYMORPHISM; ENZYME PURIFICATION; ESCHERICHIA COLI; GENOTYPING TECHNIQUE; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE; BIOSYNTHESIS; BLOOD; CELL MEMBRANE; CHEMISTRY; CYTOLOGY; ENZYME ASSAY; ENZYMOLOGY; GENE EXPRESSION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; MICROSOME; MUTATION; POLYMERASE CHAIN REACTION;

CELL MEMBRANE; DNA; ENZYME ASSAYS; ESCHERICHIA COLI; GENE EXPRESSION; GENOTYPING TECHNIQUES; HUMANS; MICROSOMES; MUTATION; NADPH-FERRIHEMOPROTEIN REDUCTASE; NICKEL; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS;

EID: 84883010354     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-321-3_19     Document Type: Article

References (19)

1. Miller WL, Agrawal V, Sandee D, Tee MK, Huang N, Choi JH, Morrissey K, Giacomini KM (2011) Consequences of POR mutations and polymorphisms. Mol Cell Endocrinol 336:174-179
2. Huang N, Agrawal V, Giacomini KM, Miller WL (2008) Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A 105: 1733-1738
3. Sandee D, Morrissey K, Agrawal V, Tam HK, Kramer MA, Tracy TS, Giacomini KM, Miller WL (2010) Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet Genomics 20:677-686
4. Agrawal V, Choi JH, Giacomini KM, Miller WL (2010) Substrate-speci fic modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet Genomics 20:611-618
5. Agrawal V, Huang N, Miller WL (2008) Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet Genomics 18:569-576
6. de Jonge H, Metalidis C, Naesens M, Lambrechts D, Kuypers DR (2011) The P450 oxidoreductase. 28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 12:1281-1291
7. Oneda B, Crettol S, Jaquenoud Sirot E, Bochud M, Ansermot N, Eap CB (2009) The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics 19:877-883
8. Daly AK, King BP, Leathart JB (2006) Genotyping for cytochrome P450 polymorphisms. Methods Mol Biol 320:193-207
9. Sandee D, Miller WL (2011) High-yield expression of a catalytically active membranebound protein: human P450 oxidoreductase. Endocrinology 152:2904-2908
10. Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, Jabs EW, Van Vliet G, Sack J, Fluck CE, Miller WL (2005) Diversity and function of mutations in P450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 76:729-749
11. van GB, Slater CE (1962) The extinction coef ficient of cytochrome c. Biochim Biophys Acta 58:593-595
12. Auchus RJ, Lee TC, Miller WL (1998) Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer. J Biol Chem 273:3158-3165
13. Wang YH, Tee MK, Miller WL (2010) Human cytochrome P450c17: single step puri fication and phosphorylation of serine 258 by protein kinase a. Endocrinology 151:1677-1684
14. Gomes LG, Huang N, Agrawal V, Mendonca BB, Bachega TA, Miller WL (2008) The common P450 oxidoreductase variant A503V is not a modi fier gene for 21-hydroxylase de ficiency. J Clin Endocrinol Metab 93:2913-2916
15. Fluck CE, Mullis PE, Pandey AV (2010) Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identi fied in patients with disordered steroid metabolism. Biochem Biophys Res Commun 401:149-153
16. Pandey AV, Kempna P, Hofer G, Mullis PE, Fluck CE (2007) Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Mol Endocrinol 21:2579-2595
17. Dong P-P, Fang Z-Z, Zhang Y-Y, Ge G-B, Mao Y-X, Zhu L-L, Qu Y-Q, Li W, Wang L-M, Liu C-X, Yang L (2011) Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib. Acta Pharmacol Sin 32:399-407
18. Kaspera R, Naraharisetti SB, Evangelista EA, Marciante KD, Psaty BM, Totah RA (2011) Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochem Pharmacol 82:681-691
19. Phillips IR, Shephard EA (eds) (2006) Cytochrome P450 protocols, 2nd edn, Methods in molecular biology. Humana, Totowa, NJ